Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Paolo Spagnolo, Jonathan A. Kropski, Mark G. Jones, et al.
Pharmacology & Therapeutics (2020) Vol. 222, pp. 107798-107798
Open Access | Times Cited: 397

Showing 1-25 of 397 citing articles:

Organs-on-chips: into the next decade
Lucie A. Low, Christine L. Mummery, Brian R. Berridge, et al.
Nature Reviews Drug Discovery (2020) Vol. 20, Iss. 5, pp. 345-361
Open Access | Times Cited: 691
H3K18 lactylation promotes the progression of arsenite-related idiopathic pulmonary fibrosis via YTHDF1/m6A/NREP
Peiwen Wang, Daxiao Xie, Tian Xiao, et al.
Journal of Hazardous Materials (2023) Vol. 461, pp. 132582-132582
Closed Access | Times Cited: 56
Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice
Lin Pan, Yiju Cheng, Wenting Yang, et al.
Inflammation (2023) Vol. 46, Iss. 4, pp. 1531-1542
Open Access | Times Cited: 48
Endocrine and metabolic factors and the risk of idiopathic pulmonary fibrosis: a Mendelian randomization study
Yan Jiang, Rumeng Chen, Shuling Xu, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 28
The impact of formaldehyde exposure on lung inflammatory disorders: Insights into asthma, bronchitis, and pulmonary fibrosis
Asif Ahmad Bhat, Muhammad Afzal, Ahsas Goyal, et al.
Chemico-Biological Interactions (2024) Vol. 394, pp. 111002-111002
Open Access | Times Cited: 23
Node-adaptive graph Transformer with structural encoding for accurate and robust lncRNA-disease association prediction
Guanghui Li, Peihao Bai, Liang Cheng, et al.
BMC Genomics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 17
Mapping spatially resolved transcriptomes in human and mouse pulmonary fibrosis
Lovisa Franzén, Martina Olsson Lindvall, Michael Hühn, et al.
Nature Genetics (2024) Vol. 56, Iss. 8, pp. 1725-1736
Open Access | Times Cited: 16
Modulating NLRP3 Inflammasomes in Idiopathic Pulmonary Fibrosis: A Comprehensive Review on Flavonoid-Based Interventions
Megh Pravin Vithalkar, Shaili Pradhan, K. Sandra, et al.
Cell Biochemistry and Biophysics (2025)
Open Access | Times Cited: 2
ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling
Junzhao Liu, Zuohong Wu, Yadong Liu, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 66
Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
Hongbo Ma, Xuyi Wu, Yi Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
Lactylation: novel epigenetic regulatory and therapeutic opportunities
Haoqin Fan, Fan Yang, Zhenghui Xiao, et al.
AJP Endocrinology and Metabolism (2023) Vol. 324, Iss. 4, pp. E330-E338
Closed Access | Times Cited: 40
The application of Aptamer in biomarker discovery
Yongshu Li, Winnie W. L. Tam, Yuanyuan Yu, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 35
Alvespimycin Exhibits Potential Anti-TGF-β Signaling in the Setting of a Proteasome Activator in Rats with Bleomycin-Induced Pulmonary Fibrosis: A Promising Novel Approach
Osama A. Mohammed, Mustafa Ahmed Abdel‐Reheim, Lobna A. Saleh, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1123-1123
Open Access | Times Cited: 30
Inhaled Lipid Nanoparticles Alleviate Established Pulmonary Fibrosis
Dongjun Li, Ang Zhao, Jiafei Zhu, et al.
Small (2023) Vol. 19, Iss. 30
Closed Access | Times Cited: 26
Magnetic liposome as a dual-targeting delivery system for idiopathic pulmonary fibrosis treatment
Xi Wang, Yuying Wang, Zhifeng Xue, et al.
Journal of Colloid and Interface Science (2023) Vol. 636, pp. 388-400
Closed Access | Times Cited: 25
The emerging roles of ferroptosis in organ fibrosis and its potential therapeutic effect
Xuege Huang, Yahui Song, Lin Wei, et al.
International Immunopharmacology (2023) Vol. 116, pp. 109812-109812
Closed Access | Times Cited: 24
Network pharmacology and molecular docking combined with widely targeted metabolomics to elucidate the potential compounds and targets of Euphorbia helioscopia seeds for the treatment of pulmonary fibrosis
Yanxia Liu, Wanqing Sun, Na Shen, et al.
Computers in Biology and Medicine (2023) Vol. 160, pp. 107007-107007
Open Access | Times Cited: 23
The mechanism of action of Botrychium (Thunb.) Sw. for prevention of idiopathic pulmonary fibrosis based on 1H-NMR-based metabolomics
Yutao Lou, Xiaozhou Zou, Zongfu Pan, et al.
Journal of Pharmacy and Pharmacology (2024) Vol. 76, Iss. 8, pp. 1018-1027
Closed Access | Times Cited: 15
The gene expression of CALD1, CDH2, and POSTN in fibroblast are related to idiopathic pulmonary fibrosis
Shufei Wu, Mengying Liu, Mingrui Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Lung regeneration: diverse cell types and the therapeutic potential
Yutian Chen, Zhen Li, Gaili Ji, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 11
Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target
Hao Zhang, Phung N. Thai, Rabindra V. Shivnaraine, et al.
Cell (2024)
Closed Access | Times Cited: 11
Nanomedicines for targeted pulmonary delivery: receptor-mediated strategy and alternatives
Wenhao Wang, Ziqiao Zhong, Zhengwei Huang, et al.
Nanoscale (2024) Vol. 16, Iss. 6, pp. 2820-2833
Closed Access | Times Cited: 10
Design, Synthesis, and Biological Evaluation of a Potent and Orally Bioavailable FGFRs Inhibitor for Fibrotic Treatment
Yue Lin, Zui Tan, Wei Wei, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117232-117232
Closed Access | Times Cited: 1
Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids
Takahiro Suezawa, Shuhei Kanagaki, Keita Moriguchi, et al.
Stem Cell Reports (2021) Vol. 16, Iss. 12, pp. 2973-2987
Open Access | Times Cited: 51
Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
Anna Valeria Samarelli, Roberto Tonelli, Alessandro Marchioni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8952-8952
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top